NCT01045551View on ClinicalTrials.gov

Open Label Pilot Study of Apremilast in Treatment of Rosacea

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2014

Conditions
Erythematotelangiectatic RosaceaPapulopustular Rosacea
Interventions
DRUG

Apremilast

20mg taken orally twice per day for 12 weeks

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Julian M. Mackay-Wiggan

OTHER